Posted by Hugh on April 25, 2018, at 9:57:49
In reply to Re: NDA Submitted for Postpartum Depression Drug, posted by SLS on April 25, 2018, at 5:38:57
Sage Therapeutics is testing an oral drug similar to brexanolone to treat major depressive disorder, postpartum depression, essential tremor, Parkinson's, and insomnia. Here's a description of it from Sage's website:
"SAGE-217 is a novel, selective, next generation GABAA positive allosteric modulator that shares similar pharmacology properties to brexanolone. We are initially developing SAGE-217 as a once-daily, oral therapy for treatment of various CNS disorders."
The phase 2 clinical trial results for SAGE-217 for major depressive disorder were released late last year.
"At day 15, 64% of patients in the treatment group achieved remission compared to 23% for placebo (p=0.0005). Other secondary endpoints were also met."
poster:Hugh
thread:1098323
URL: http://www.dr-bob.org/babble/20180331/msgs/1098339.html